Description
PsyMed Ventures is an early-stage venture capital firm focused on mental health, behavioral health, and neuroscience-driven technologies, backing companies that improve access, outcomes, and quality of care across psychiatry, psychology, and brain health. The firm invests as a seed-stage specialist and typically takes institutional-level ownership aligned with active involvement.
Seed: Core focus; PsyMed most often invests at seed and early institutional rounds.
Pre-Seed: Selective participation when clinical insight, founder credibility, or proprietary approach is strong.
Series A: Occasional follow-on participation in breakout portfolio companies.
Typical Check Size: ~$500K–$2M at seed.
Typical Ownership Taken: ~5%–10% at entry.
Upper Range (When Leading/Co-Leading): Up to ~12% in smaller seed rounds.
Ownership Style: Minority but meaningful institutional stake.
Equity Structure: Priced equity preferred; SAFEs/notes used selectively at pre-seed.
Board Seats: Occasional board or observer role depending on ownership and stage.
Control: No control rights; active governance when leading.
Submission Method: Warm introductions preferred; selective inbound via website or healthcare ecosystem referrals.
Lead Position: Comfortable co-leading or leading seed rounds when conviction is high.
Review Cadence: Rolling, thesis-driven.
Eligibility
Sector Focus: Mental health, behavioral health, psychiatry, psychology, digital therapeutics, care delivery models, provider enablement, neurotech-adjacent (non-invasive).
Geography: Primarily U.S.-based companies.
Stage: Seed preferred; strong pre-seed considered.
Company Profile: Venture-scale businesses with clinical insight, early validation, or pilot traction.
Team: Founders with clinical, scientific, or lived-experience insight paired with strong execution.
Process
Initial Intake: Review of clinical problem, evidence base, differentiation, and founder credibility.
Partner Diligence: Deep dives on clinical validity, regulatory pathway, reimbursement, and GTM.
Market & Impact Review: Assessment of scale potential and measurable patient/provider outcomes.
Deal Structuring: Ownership sized to support hands-on engagement and follow-on participation.
What an Applicant can Obtain
Strategic Capital: Seed capital sized for meaningful runway and milestones.
Domain Expertise: Deep mental-health and healthcare commercialization guidance.
Governance Support: Active involvement at the seed stage.
Follow-On Capital: High likelihood of pro-rata participation.
